## REMARKS

Claims 1-35 are pending in the application. Claims 2-7 and 9-35 have been withdrawn. The elected claims set forth, herein, are merely to comply with the Restriction Requirement and is not to be construed as surrender of any subject matter in the instant application. Applicants hereby reserve the right to pursue the subject matter of the canceled claims in one or more divisional patent applications.

Restriction Requirement

In the above-identified Office Action, the examiner set forth a restriction requirement and required election of one of the following groups under 35 U.S.C. § 121:

Group I, claim(s) 1 and 8, drawn to the isolated polypeptide of SEQ ID NO: 3 or an allele (sic) or derivative thereof.

Group II, claim(s) 1, 9 and 10, drawn to the isolated polypeptide of SEQ ID NO: 4 or an allele (sic) or derivative thereof.

Group III, claim(s) 1, 9 and 10, drawn to the isolated polypeptide of SEQ ID NO: 6 or an allele (sic) or derivative thereof.

Group IV, claim(s) 1 and 8, drawn to the isolated polypeptide of SEQ ID NO: 7 or an allele (sic) or derivative thereof.

Group V, claim(s) 2-6, 11-15, and 23, drawn to the isolated polynucleotide of SEQ ID NO: 1 or a vector or host cell comprising the polynucleotide.

Group VI, claim(s) 2-5, 7 and 11-15, drawn to the isolated polynucleotide of SEQ ID NO: 2 or a vector or host cell comprising the polynucleotide.

Group VI, claim(s) 2-5, 7 and 11-15, drawn to the isolated polynucleotide of SEQ ID NO: 5 or a vector or host cell comprising the polynucleotide.

Group VIII, claim(s) 2-6, 11-15, and 23, drawn to the isolated polynucleotide of SEQ ID NO: 7 or a vector or host cell comprising the polynucleotide.

Group IX, claim(s) 16 and 24, drawn to the use of the polynucleotide of SEQ ID NO: 1 for making transgenic mammals.

Group X, claim(s) 16 and 24, drawn to the use of the polynucleotide of SEQ ID NO: 2 for making transgenic mammals.

Group XI, claim(s) 16 and 24, drawn to the use of the polynucleotide of SEQ ID NO: 5 for making transgenic mammals.

Group XII, claim(s) 16 and 24, drawn to the use of the polynucleotide of SEQ ID NO: 7 for making transgenic mammals.

Group XIII, claim(s) 17 and 25, drawn to the use of the polypeptide of SEQ ID NO: 3 for making an antibody to it.

Group XIV, claim(s) 17, drawn to the use of the polypeptide of SEQ ID NO: 4 for making an antibody to it.

Group XV, claim(s) 17, drawn to the use of the polypeptide of SEQ ID NO: 6 for making an antibody to it.

Group XVI, claim(s) 17 and 25, drawn to the use of the polypeptide of SEQ ID NO: 8 for making an antibody to it.

Group XVII, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 3 in a diagnostic method.

Group XVIII, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 3 in a therapeutic treatment method.

Group XIX, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 3 in a cosmetic treatment method.

Group XX, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 4 in a diagnostic method.

Group XXI, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 4 in a therapeutic treatment method.

Group XXII, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 4 in a cosmetic treatment method.

Group XXIII, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 6 in a diagnostic method.

Group XXIV, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 6 in a therapeutic treatment method.

Group XXV, claim(s) 18, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 6 in a cosmetic treatment method.

Group XXVI, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 8 in a diagnostic method.

Group XXVII, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 8 in a therapeutic treatment method.

Group XXVIII, claim(s) 18 and 26, drawn to the use of an antibody to the polypeptide of SEQ ID NO: 8 in a. cosmetic treatment method.

Group XXIX, claim(s) 19 and 27, drawn to an antibody to the polypeptide of SEQ ID NO: 3.

Group XXX, claim(s) 19, drawn to an antibody to the polypeptide of SEQ ID NO: 4.

Group XXXI, claim(s) 19, drawn to an antibody to the polypeptide of SEQ ID NO: 6.

Group XXXII, claim(s) 19 and 27, drawn to an antibody to the polypeptide of SEQ ID NO: 8.

Group XXXIII, claim(s) 20, 28 and 32, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polynucleotide of SEQ ID NO: 1.

Group XXXIV, claim(s) 20, 28 and 32, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polynucleotide of SEQ ID NO: 2.

Group XXXV, claim(s) 20, 28 and 32, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polynucleotide of SEQ ID NO: 5.

Group XXXVI, claim(s) 20, 28 and 32, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polynucleotide of SEQ ID NO: 7.

Group XXXVII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 1 in a diagnostic method.

Group XXXVIII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 1 in a therapeutic treatment method.

Group XXXIX, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 1 in a cosmetic treatment method.

Group XXXX, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 2 in a diagnostic method.

Group XXXXI, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 2 in a therapeutic treatment method.

Group XXXXII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 2 in a cosmetic treatment method.

Group XXXXIII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 5 in a diagnostic method.

Group XXXXIV, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 5 in a therapeutic treatment method.

Group XXXXV, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 5 in a cosmetic treatment method.

Group XXXXVI, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 7 in a diagnostic method.

Group XXXXVII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 7 in a therapeutic treatment method.

Group XXXXVIII, claim(s) 21, drawn to the use of the polynucleotide of SEQ ID NO: 7 in a cosmetic treatment method.

Group XXXXIX, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 3 in a diagnostic method.

Group L, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 3 in a therapeutic treatment method.

Group LI, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 3 in a cosmetic treatment method.

Group LII, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 4 in a diagnostic method.

Group LIII, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 4 in a therapeutic treatment method.

Group LIV, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 4 in a cosmetic treatment method.

Group LV, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 6 in a diagnostic method.

Group LVI, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 6 in a therapeutic treatment method.

Group LVII, claim(s) 22, drawn to the use of the polypeptide of SEQ ID NO: 6 in a cosmetic treatment method.

Group LVIII, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 1 in a diagnostic method.

Group LIX, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 1 in a therapeutic treatment method.

Group LX, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 1 in a cosmetic treatment method.

Group LXI, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 7 in a diagnostic method.

Group LXI, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 7 in a therapeutic treatment method.

Group LXIII, claim(s) 29, drawn to the use of an oligonucleotide from SEQ ID NO: 7 in a cosmetic treatment method.

Group LXIV, claim(s) 30, 31 and 35, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polypeptide of SEQ ID NO: 3.

Group LXV, claim(s) 30, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polypeptide of SEQ ID NO: 4.

Group LXVI, claim(s) 30, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polypeptide of SEQ ID NO: 6.

Group LXVII, claim(s) 30, 31 and 35, drawn to a reagent for detecting a keratinocyte protein that is manufactured with the polypeptide of SEQ ID NO: 8.

Group LXVIII, claim(s) 33, drawn to the use of the polypeptide of SEQ ID NO: 3 for identifying binding partners that affect the function or expression of the polypeptide.

Group LXIX, claim(s) 33, drawn to the use of the polypeptide of SEQ ID NO: 8 for identifying binding partners that affect the function or expression of the polypeptide.

Group LXX, claim(s) 34, drawn to the use of the polynucleotide of SEQ ID NO: 1 for identifying binding partners that affect the function or expression of the polynucleotide.

Group LXXI, claim(s) 34, drawn to the use of the polynucleotide of SEQ ID NO: 2 for identifying binding partners that affect the function or expression of the polynucleotide.

Group LXXII, claim(s) 34, drawn to the use of the polynucleotide of SEQ ID NO: 5 for identifying binding partners that affect the ~function or expression of the polynucleotide.

Group LXXIII, claim(s) 34, drawn to the use of the polynucleotide of SEQ ID NO: 7 for identifying binding partners that affect the function or expression of the polynucleotide.

In response, Applicants elect Group IV , claims 1 and 8, drawn to the isolated polypeptide of **SEQ ID NO: 8** or an allele (sic) or derivative thereof. Applicants have amended claim 8 to be directed to SEQ ID NO: 8, **a polypeptide**. Claim 1 does not recite SEQ ID NO: 7 which is the **nucleic acid sequence**. Therefore, claim 8 has been amended so that both claims 1 and 8 recite SEQ ID NO: 8. This election is made with traverse as Applicants elect SEQ ID NO: 8 and not SEQ ID NO: 7. Amendment of the claim 8 to be directed to SEQ ID NO: 8 does not impose a burden on the Examiner and rather, simplifies the search to be conducted as SEQ ID NO: 7 is the nucleic acid coding for the polypeptide, SEQ ID NO: 8. See, for example, page 4, paragraph [0012]. Therefore, the amendment is directed to a **polypeptide (SEQ ID NO: 8)** rather than the **nucleic acid sequence (SEQ ID NO: 7)**. No new matter has been added by virtue of this amendment and its entry is respectfully requested.

The elected claims set forth, herein, are merely to comply with the Restriction Requirement and is not to be construed as surrender of any subject matter in the instant application. Applicants hereby reserve the right to pursue the subject matter of the

canceled claims in one or more divisional patent applications. Applicants invite the Examiner to call the undersigned if it is believed that the above restriction election is incomplete or improper in any way, or if a telephonic interview will expedite the prosecution of the application to an allowance.

Although, Applicants believe that no further extensions of time are required with submission of this paper, Applicants request that this submission also be considered as a petition for any extensions of time if necessary. The Commissioner for Patents and Trademarks is hereby authorized to charge the amount due for any retroactive extensions of time and any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing or during prosecution of this application to Deposit Account No. 50-0951.

Respectfully submitted,
AKERMAN SENTERFITT

Date: May 12, 2006

Nicholas A. Zachariades, Ph.D.
Reg. No. 56,712
AKERMAN SENTERFITT
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000

Docket No. 9725-6